Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
APOKYN vs INJECTAPAP
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.
Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.
Treatment of acute, intermittent hypomobility episodes (off episodes) in patients with advanced Parkinson's disease
Management of mild to moderate pain,Reduction of fever
Subcutaneous injection: 0.2 m L (2 mg) as a test dose, then 0.1-0.6 m L (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 m L (6 mg); maximum daily dose: 2.0 m L (20 mg).
1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.
Terminal elimination half-life approximately 30–60 minutes (range 0.5–1 hour); clinically, rapid clearance necessitates continuous or frequent dosing for sustained effect
2-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
Primarily hepatic via N-demethylation to norapomorphine; also undergoes sulfation and glucuronidation. CYP enzymes involved include CYP2B6, CYP2C19, and CYP3A4.
Primarily metabolized in the liver via conjugation (glucuronidation and sulfation) at therapeutic doses; a minor pathway via cytochrome P450 (CYP2E1, CYP1A2, and CYP3A4) produces a toxic metabolite (NAPQI) which is normally detoxified by glutathione.
Renal (approx. 90% as metabolites and unchanged drug; <5% unchanged in urine); biliary/fecal (minor, <10%)
Renal: 2-5% unchanged; hepatic metabolism to glucuronide and sulfate conjugates, then renal excretion of metabolites. Biliary/fecal: minimal (<5%).
Approximately 99% bound to plasma proteins (primarily albumin)
10-25% bound to albumin at therapeutic concentrations.
Approximately 1.5–2 L/kg (wide distribution, extensive tissue binding)
0.8-1.0 L/kg; suggests distribution into total body water.
Subcutaneous injection: approximately 100% (complete absorption); oral: negligible (<2%) due to extensive first-pass metabolism; intravenous: 100%
IV: 100%; oral: 60-90% (first-pass metabolism); rectal: 30-50%.
No specific dose adjustment recommended; use with caution in renal impairment. Data for GFR-based modifications are insufficient.
For GFR 30-60 m L/min: no adjustment; for GFR <30 m L/min: extend interval to every 8 hours; maximum 3 g per day.
No specific dose adjustment recommended; use with caution in moderate to severe hepatic impairment (Child-Pugh B or C).
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%, maximum 2 g per day; Child-Pugh C: contraindicated.
Not established; safety and efficacy in pediatric patients have not been studied.
For weight ≥50 kg: 1 g every 6 hours; for weight 10-50 kg: 15 mg/kg every 6 hours; for weight <10 kg: 7.5 mg/kg every 6 hours; all intravenous.
No specific dose adjustment; elderly patients may be more sensitive to adverse effects; initiate at low end of dosing range.
No specific dose adjustment required; consider decreased hepatic function and concomitant medications; maximum 3 g per day for patients with risk factors for hepatotoxicity.
None
Acetaminophen has been associated with cases of acute liver failure, hepatotoxicity is primarily due to overdose. Risk is increased in patients with underlying liver disease, chronic alcohol use, and those taking multiple acetaminophen-containing products.
Cardiovascular effects: severe hypotension, syncope, bradycardia, and QT prolongation; monitor blood pressure and ECG,Nausea and vomiting: almost universal; pre-treatment with antiemetic (e.g., trimethobenzamide) required,Falling asleep during activities of daily living: risk of sudden sleep onset,Psychiatric effects: hallucinations, confusion, psychosis; may exacerbate existing disorders,Dyskinesias: may be precipitated or worsened,Impulse control disorders: compulsive behaviors reported,Hemolytic anemia: rare but severe risk; monitor blood counts,Skin reactions: injection site reactions, panniculitis, and pain
Risk of hepatotoxicity, especially with doses exceeding 4 g/day or in patients with liver impairment,Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and acute generalized exanthematous pustulosis,Hypersensitivity reactions,Use caution in patients with G6PD deficiency,Avoid use with other acetaminophen-containing products
Concurrent use of 5-HT3 antagonists (e.g., ondansetron, granisetron),Hypersensitivity to apomorphine or any component of the product,Concomitant use of drugs that prolong QT interval
Hypersensitivity to acetaminophen or any component of the formulation
Avoid high-protein meals as they may delay absorption; take on an empty stomach for consistent response. No specific food contraindications.
No significant food interactions. However, concurrent ingestion of alcohol may increase risk of hepatotoxicity; avoid alcohol while on therapy.
Apomorphine is classified as Pregnancy Category C. In animal studies, maternal toxicity and fetal effects (reduced fetal weight, delayed ossification) were observed at doses ≥3 mg/kg/day (approximately 0.3 times the maximum recommended human dose). No adequate and well-controlled studies exist in pregnant women. For first trimester: potential risk based on animal data; second and third trimesters: unknown risk. Use only if potential benefit justifies potential risk to fetus.
FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major malformations. Second and third trimesters: chronic high-dose use may be associated with increased risk of childhood asthma and attention-deficit/hyperactivity disorder (ADHD). Overdose poses risk of maternal and fetal hepatotoxicity.
It is not known if apomorphine is excreted in human milk. No M/P ratio available. Due to potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account importance of drug to mother.
Acetaminophen is excreted into breast milk in low concentrations (M/P ratio approximately 0.91-1.42). Reported infant dose is less than 2% of maternal weight-adjusted dose. Considered compatible with breastfeeding. Use lowest effective dose for shortest duration.
No established dosing adjustments for pregnancy. Pharmacokinetic changes during pregnancy (increased volume of distribution, renal clearance) may reduce drug exposure; however, no dose adjustment guidelines are available. Individualize based on clinical response and tolerability.
No dose adjustment required for standard therapeutic use. Increased clearance in pregnancy may require shorter dosing intervals for pain control; consider maximum daily dose of 3 g/day instead of 4 g/day. Avoid prolonged use >48 hours without medical supervision.
Administer with an antiemetic (e.g., trimethobenzamide) to prevent severe nausea/vomiting. Use extreme caution in patients with prolonged QT interval. Injection sites must be rotated; do not inject into areas with bruising, redness, or hard lumps. Onset of effect is within 10 minutes but duration is short (about 1 hour). Monitor for orthostatic hypotension and dyskinesias.
Acetaminophen injection is indicated for treatment of acute pain and fever. Use with caution in hepatic impairment. Avoid in patients with severe active liver disease. Monitor liver function tests with prolonged use. Do not exceed maximum daily dose (4 g/day in adults). Use the smallest effective dose for the shortest duration.
Take exactly as prescribed; do not use more often than directed.,Administer only into the abdomen, thigh, or upper arm; rotate injection sites.,Do not inject into areas with broken, bruised, or red skin.,Avoid driving or operating machinery until you know how the drug affects you.,Rise slowly from sitting or lying to reduce dizziness.,Report severe nausea, vomiting, hallucinations, or compulsive behaviors immediately.
Do not take more than the recommended dose. Overdose can cause severe liver damage.,Inform your healthcare provider if you have liver disease or drink alcohol regularly.,Check other medications for acetaminophen to avoid double dosing.,Seek immediate medical attention if you experience signs of liver injury (e.g., yellowing skin/eyes, dark urine, upper stomach pain).,This medication is administered by intravenous infusion; do not attempt self-administration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about APOKYN vs INJECTAPAP, answered by our medical review team.
APOKYN is a Dopamine Agonist that works by Apomorphine is a non-ergoline dopamine agonist that stimulates dopamine D2 and D1 receptors. It also activates D3, D4, and D5 receptors and has some serotonergic and adrenergic activity.. INJECTAPAP is a Non-Opioid Analgesic that works by Acetaminophen is a centrally acting analgesic and antipyretic; its exact mechanism is not fully understood but involves inhibition of cyclooxygenase (COX) enzymes in the central nervous system and modulation of descending serotonergic pathways. It does not have significant anti-inflammatory activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between APOKYN and INJECTAPAP depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of APOKYN is: Subcutaneous injection: 0.2 m L (2 mg) as a test dose, then 0.1-0.6 m L (1-6 mg) as needed for episodes of hypomobility; maximum single dose: 0.6 m L (6 mg); maximum daily dose: 2.0 m L (20 mg).. The standard adult dose of INJECTAPAP is: 1 g intravenous every 6 hours or 650 mg intravenous every 4 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between APOKYN and INJECTAPAP in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. APOKYN is classified as Category C. Apomorphine is classified as Pregnancy Category C. In animal studies, maternal toxicity and fetal effects (reduced fetal weight, delayed ossification) were observed at doses ≥3 mg/. INJECTAPAP is classified as Category C. FDA Category C. Acetaminophen crosses the placenta. No evidence of teratogenicity in humans with standard doses. First trimester: limited data suggest no increased risk of major ma. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.